Excerpt from article:  "Over 10% of the biotechnology products currently in the pipeline target high-risk infectious agents such as HIV and TB.  As this type of drug research ramps up, biopharmaceutical companies are becoming increasingly sensitive to the dangers that accompany handing these agents..."